Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11354403 | 0.87 | POLB (0.61) | L3MBTL1POLBSMN1; SMN2NAMPTKDM4E | |
| SCHEMBL11353914 | 0.85 | SMN1; SMN2 (0.73) | L3MBTL1POLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL11355371 | 0.85 | POLB (0.59) | L3MBTL1POLBSMN1; SMN2PKMNAMPT | |
| SCHEMBL7435574 | 0.85 | POLB (0.59) | L3MBTL1POLBSMN1; SMN2NAMPTMAPT | |
| SCHEMBL11355367 | 0.85 | POLB (0.59) | L3MBTL1POLBSMN1; SMN2NAMPTMEN1 | |
| SCHEMBL11363142 | 0.77 | L3MBTL1 (0.74) | L3MBTL1POLBSMN1; SMN2HTTNAMPT | |
| SCHEMBL7628422 | 0.77 | ALDH1A1 (0.64) | L3MBTL1POLBSMN1; SMN2MEN1KMT2A | |
| Trocimine SCHEMBL9534 | 0.76 | POLB (0.72) | L3MBTL1POLBSMN1; SMN2HTTPKM | |
| SCHEMBL10115996 | 0.75 | POLB (0.57) | L3MBTL1POLBSMN1; SMN2NAMPTKMT2A | |
| SCHEMBL10115650 | 0.75 | POLB (0.57) | L3MBTL1POLBSMN1; SMN2NAMPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106048-B2 | protozoal infestations in humans and animals, by bacteria, viruses or proteinaceous agents; neurological diseases or disorders; ischemia and/or reperfusion injury; 4-(4-Ethoxycarbonyl-4,5-dihydro-thiazol-2-yl)-piperidine-1-carboxylic acid t-butyl ester | 4SC AG (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2012-01-26 | — | — | US | disclosed |
| EP-1753721-A1 | AROYL-O-PIPERIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES-RELATED PROBLEMS | MERCK PATENT GmbH (DE) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005121091-A1 | AROYL-O-PIPERIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES-RELATED PROBLEMS | MERCK PATENT GMBH (DE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKB2, NFKBIA, NFRKB | L3MBTL1 2753/4885POLB 731/4885SMN1; SMN2 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.